Dyadic initiates subject dosing in Phase I trial of Covid-19 booster

Dyadic International has initiated subject dosing in its Phase I clinical trial of the Covid-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate DYAI-100.

The double blind, randomised, placebo-controlled trial will demonstrate DYAI-100’s clinical safety and antibody response in humans.